+6.5%
IEMG vs MRNA
+909.7%
-903.1%
-17.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.6% | -6.5% | +0.9% | -5.5% |
| 7D | -7.4% | +8.4% | -15.8% | -7.6% |
| 30D | -14.9% | +28.8% | -43.7% | -15.3% |
| 3M | -11.6% | +329.2% | -340.8% | -15.9% |
| 6M | -11.1% | +416.9% | -428.0% | -17.9% |
| YTD | +6.0% | +718.8% | -712.7% | -3.9% |
| 1Y | +6.5% | +924.9% | -918.3% | -5.6% |
| All | +6.5% | +909.7% | -903.1% | -5.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling